Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160050/S012

Barricaid Annular Closure Device

Intrinsic Therapeutics · Decision date Mar 24, 2026

FDA DECISIONP160050/S012

What did the FDA decide?

FDA records P160050/S012 as a supplement to PMA P160050, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 24, 2026.

FDA approval order statement

approval for an alternate manufacturing process and new supplier affecting critical components of the Barricaid implant device/delivery system, specifically the 8mm Delivery Sheath
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Mar 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160050/S012
Regulatory pathway
PMA supplement
Product code
QES
Decision code
OK30
Decision date
Mar 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Reherniation reduction device.

Product code
QES
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160050/S010 · Related supplement

    Barricaid Annular Closure Device

  2. P160050/S011 · Related supplement

    Barricaid Annular Closure Device

  3. P160050/S012 received

    Application receipt date recorded by FDA.

  4. P160050/S012 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P160050. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160050

Product / regulatory recordCompanyPathwayDecision dateSource
Intrinsic TherapeuticsPMA supplementOct 9, 2025FDA
Intrinsic TherapeuticsPMA supplementDec 18, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Intrinsic Therapeutics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
30 Commerce Way, Woburn, MA, 01801

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records